DiaMedica Therapeutics Inc. (DMAC) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts DMAC Hot Sheet
Join SI Premium – FREE
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).
For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Baxter raises tender offer cap to $600M for senior notes
- Iridex Corp (IRIX) Misses Q2 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
